Glucagon-like peptide-1: Glucose homeostasis and beyond

Annual Review of Physiology

Volumn 76, Issue , 2014, Pages 535-559

  Cho, Young Min ^a   Fujita, Yukihiro ^b   Kieffer, Timothy J ^c  

^a Seoul National University College of Medicine   (South Korea)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Diabetes mellitus; Dipeptidyl peptidase 4 inhibitor; Glucose metabolism; Incretin

Indexed keywords

ANIMALS; BIOMIMETICS; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HOMEOSTASIS; HUMANS; PANCREAS;

EID: 84894148643     PISSN: 00664278     EISSN: 15451585     Source Type: Book Series    
DOI: 10.1146/annurev-physiol-021113-170315     Document Type: Review

References (161)

1. McIntyre N, Holdsworth CD, Turner DS. 1964. New interpretation of oral glucose tolerance. Lancet 2:20-211
2. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, et al. 1986. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J. Clin. Endocrinol. Metab. 63:492-988
3. Bagger JI, Knop FK, Lund A, Vestergaard H, Holst JJ, Vilsboll T. 2011. Impaired regulation of the incretin effect in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 96:737-455
4. Brown JC. 1971.Agastric inhibitory polypeptide. I.The amino acid composition and the tryptic peptides. Can. J. Biochem. 49:255-611
5. Brown JC, Dryburgh Jr. 1971. A gastric inhibitory polypeptide. II. The complete amino acid sequence. Can. J. Biochem. 49:867-722
6. Dupre J, Ross SA, Watson D, Brown JC. 1973. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J. Clin. Endocrinol. Metab. 37:826-288
7. Kieffer TJ, Habener JF. 1999. The glucagon-like peptides. Endocr. Rev. 20:876-9133
8. CreutzfeldtW. 1979. The incretin concept today. Diabetologia 16:75-855
9. Cho YM, Merchant CE, Kieffer TJ. 2012. Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacol. Ther. 135:247-788
10. Meier JJ, Nauck MA. 2010. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired β-cell function? Diabetes 59:1117-255
11. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. 1993. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Investig. 91:301-77
12. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. 2011. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes:What is up, what is down? Diabetologia 54:10-188
13. Mortensen K, Christensen LL, Holst JJ, Orskov C. 2003. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul. Pept. 114:189-966
14. Fujita Y, Chui JW, King DS, Zhang T, Seufert J, et al. 2008. Pax6 and Pdx1 are required for production of glucose-dependent insulinotropic polypeptide in proglucagon-expressing L cells. Am. J. Physiol. Endocrinol. Metab. 295:E648-577
15. Bell GI, Santerre RF,Mullenbach GT. 1983. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 302:716-188
16. Rouille Y, Martin S, Steiner DF. 1995. Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide. J. Biol. Chem. 270:26488-966
17. Ugleholdt R, Zhu X, Deacon CF, Orskov C, Steiner DF, Holst JJ. 2004. Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1. Endocrinology 145:1349-555
18. Zhu X, Zhou A, Dey A, Norrbom C, Carroll R, et al. 2002. Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects. Proc. Natl. Acad. Sci. USA 99:10293-988
19. ShaoW,Wang D, Chiang YT, Ip W, Zhu L, et al. 2013. TheWnt signaling pathway effector TCF7L2 controls gut and brain proglucagon gene expression and glucose homeostasis. Diabetes 62:789-8000
20. Hill ME, Asa SL, Drucker DJ. 1999. Essential requirement for Pax6 in control of enteroendocrine proglucagon gene transcription. Mol. Endocrinol. 13:1474-866
21. Daoudi M, Hennuyer N, Borland MG, Touche V, Duhem C, et al. 2011. PPAR β/ activation induces enteroendocrine L cell GLP-1 production. Gastroenterology 140:1564-744
22. Lotfi S, Li Z, Sun J, Zuo Y, Lam PP, et al. 2006. Role of the exchange protein directly activated by cyclic adenosine 5 -monophosphate (Epac) pathway in regulating proglucagon gene expression in intestinal endocrine L cells. Endocrinology 147:3727-366
23. Sjolund K, Sanden G, Hakanson R, Sundler F. 1983. Endocrine cells in human intestine: an immunocytochemical study. Gastroenterology 85:1120-300
24. Roberge JN, Brubaker PL. 1993. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology 133:233-400
25. Hansen L, Holst JJ. 2002. The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum. A duodeno-ileal loop? Regul. Pept. 110:39-455
26. Shima K, Suda T, Nishimoto K, Yoshimoto S. 1990. Relationship between molecular structures of sugars and their ability to stimulate the release of glucagon-like peptide-1 from canine ileal loops. Acta Endocrinol. 123:464-700
27. Vozzo R, Baker B, Wittert GA, Wishart JM, Morris H, et al. 2002. Glycemic, hormone, and appetite responses to monosaccharide ingestion in patients with type 2 diabetes. Metabolism 51:949-577
28. Gorboulev V, Schurmann A, Vallon V, Kipp H, Jaschke A, et al. 2012. Na+-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61:187-966
29. Moriya R, Shirakura T, Ito J, Mashiko S, Seo T. 2009. Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice. Am. J. Physiol. Endocrinol. Metab. 297:E1358-655
30. Jang HJ, Kokrashvili Z, Theodorakis MJ, Carlson OD, Kim BJ, et al. 2007. Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc. Natl. Acad. Sci. USA 104:15069-744
31. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, et al. 2009. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 10:167-777
32. Fujita Y, Wideman RD, Speck M, Asadi A, King DS, et al. 2009. Incretin release from gut is acutely enhanced by sugar but not by sweeteners in vivo. Am. J. Physiol. Endocrinol. Metab. 296:E473-799
33. Margolskee RF, Dyer J, Kokrashvili Z, Salmon KS, Ilegems E, et al. 2007. T1R3 and gustducin in gut sense sugars to regulate expression of Na+-glucose cotransporter 1. Proc.Natl. Acad. Sci. USA 104:15075-800
34. O'Donovan D, Horowitz M, Russo A, Feinle-Bisset C, Murolo N, et al. 2004. Effects of lipase inhibition on gastric emptying of, and on the glycaemic, insulin and cardiovascular responses to, a high-fat/ carbohydrate meal in type 2 diabetes. Diabetologia 47:2208-144
35. Iakoubov R, Izzo A, Yeung A, Whiteside CI, Brubaker PL. 2007. Protein kinase C is required for oleic acid-induced secretion of glucagon-like peptide-1 by intestinal endocrine L cells. Endocrinology 148:1089-988
36. Iakoubov R, Ahmed A, Lauffer LM, Bazinet RP, Brubaker PL. 2011. Essential role for protein kinase Cin oleic acid-induced glucagon-like peptide-1 secretion in vivo in the rat. Endocrinology 152:1244-522
37. Edfalk S, Steneberg P, Edlund H. 2008. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 57:2280-877
38. Leifke E, Naik H, Wu J, Viswanathan P, Demanno D, et al. 2012. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Clin. Pharmacol. Ther. 92:29-399
39. Tanaka T, Yano T, Adachi T, Koshimizu TA, Hirasawa A, Tsujimoto G. 2008. Cloning and characterization of the rat free fatty acid receptor GPR120: in vivo effect of the natural ligand on GLP-1 secretion and proliferation of pancreatic βcells. Naunyn Schmiedeb. Arch. Pharmacol. 377:515-222
40. Morishita M, Tanaka T, Shida T, Takayama K. 2008. Usefulness of colon targeted DHA and EPA as novel diabetes medications that promote intrinsic GLP-1 secretion. J. Control. Release 132:99-1044
41. Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, et al. 2005. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat. Med. 11:90-944
42. Chu ZL, Carroll C, Alfonso J, Gutierrez V, He H, et al. 2008. A role for intestinal endocrine cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology 149:2038-477
43. Lauffer LM, Iakoubov R, Brubaker PL. 2009. GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 58:1058-666
44. Katz LB, Gambale JJ, Rothenberg PL, Vanapalli SR, Vaccaro N, et al. 2012. Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes. Diabetes Obes. Metab. 14:709-166
45. Gribble FM. 2012. The gut endocrine system as a coordinator of postprandial nutrient homoeostasis. Proc. Nutr. Soc. 71:456-622
46. Adrian TE, Gariballa S, Parekh KA, Thomas SA, Saadi H, et al. 2012. Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers. Diabetologia 55:2343-477
47. Katsuma S, Hirasawa A, Tsujimoto G. 2005. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in amurine enteroendocrine cell line STC-1. Biochem. Biophys. Res. Commun. 329:386-900
48. Tazoe H, Otomo Y, Kaji I, Tanaka R, Karaki SI, Kuwahara A. 2008. Roles of short-chain fatty acids receptors, GPR41 and GPR43 on colonic functions. J. Physiol. Pharmacol. 59(Suppl. 2):251-622
49. Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, et al. 2012. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61:364-711
50. Reimer RA,McBurneyMI. 1996. Dietary fiber modulates intestinal proglucagon messenger ribonucleic acid and postprandial secretion of glucagon-like peptide-1 and insulin in rats. Endocrinology 137:3948-566
51. Massimino SP, McBurney MI, Field CJ, Thomson AB, Keelan M, et al. 1998. Fermentable dietary fiber increases GLP-1 secretion and improves glucose homeostasis despite increased intestinal glucose transport capacity in healthy dogs. J. Nutr. 128:1786-933
52. Rocca AS, Brubaker PL. 1999. Role of the vagus nerve inmediating proximal nutrient-induced glucagonlike peptide-1 secretion. Endocrinology 140:1687-944
53. Anini Y,Hansotia T, Brubaker PL. 2002. Muscarinic receptors control postprandial release of glucagonlike peptide-1: in vivo and in vitro studies in rats. Endocrinology 143:2420-266
54. Anini Y, Brubaker PL. 2003. Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells. Endocrinology 144:3244-500
55. Chisholm C, Greenberg GR. 2002. Somatostatin-28 regulates GLP-1 secretion via somatostatin receptor subtype 5 in rat intestinal cultures. Am. J. Physiol. Endocrinol. Metab. 283:E311-177
56. Liu S, Liu R, Chiang YT, Song L, Li X, et al. 2012. Insulin detemir enhances proglucagon gene expression in the intestinal L cells via stimulating β-catenin and CREB activities. Am. J. Physiol. Endocrinol. Metab. 303:E740-511
57. Anini Y, Brubaker PL. 2003. Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes 52:252-599
58. Simpson AK, Ward PS, Wong KY, Collord GJ, Habib AM, et al. 2007. Cyclic AMP triggers glucagonlike peptide-1 secretion from the GLUTag enteroendocrine cell line. Diabetologia 50:2181-899
59. Hansen L, Hartmann B, Mineo H, Holst JJ. 2004. Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum. Regul. Pept. 118:11-188
60. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, et al. 2006. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 91:4612-199
61. El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Foley J, et al. 2007. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucoseinduced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. J. Clin. Endocrinol. Metab. 92:4165-711
62. Orskov C, Holst JJ, Poulsen SS, Kirkegaard P. 1987. Pancreatic and intestinal processing of proglucagon in man. Diabetologia 30:874-811
63. Suda K, Takahashi H, Fukase N, Manaka H, Tominaga M, Sasaki H. 1989. Distribution and molecular forms of glucagon-like peptide in the dog. Life Sci. 45:1793-988
64. Wideman RD, Yu IL, Webber TD, Verchere CB, Johnson JD, et al. 2006. Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1). Proc. Natl. Acad. Sci. USA 103:13468-733
65. Hansen AM, Bodvarsdottir TB, Nordestgaard DN, Heller RS, Gotfredsen CF, et al. 2011. Upregulation of cell glucagon-like peptide 1 (GLP-1) in Psammomys obesus -an adaptive response to hyperglycaemia? Diabetologia 54:1379-877
66. Marchetti P, Lupi R, Bugliani M, Kirkpatrick CL, Sebastiani G, et al. 2012. A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia 55:3262-722
67. Nie Y, Nakashima M, Brubaker PL, Li QL, Perfetti R, et al. 2000. Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic rats. J. Clin. Investig. 105:955-655
68. Gelling RW, Du XQ, Dichmann DS, Romer J, Huang H, et al. 2003. Lower blood glucose, hyperglucagonemia, and pancreatic cell hyperplasia in glucagon receptor knockout mice. Proc. Natl. Acad. Sci. USA 100:1438-433
69. Parker JC, Andrews KM, Allen MR, Stock JL, McNeish JD. 2002. Glycemic control inmice with targeted disruption of the glucagon receptor gene. Biochem. Biophys. Res. Commun. 290:839-433
70. Mu J, Jiang G, Brady E, Dallas-Yang Q, Liu F, et al. 2011. Chronic treatment with a glucagon receptor antagonist lowers glucose andmoderately raises circulating glucagon and glucagon-like peptide 1without severe cell hypertrophy in diet-induced obese mice. Diabetologia 54:2381-911
71. Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, et al. 2011. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and cells. Nat. Med. 17:1481-899
72. Vilsboll T, Agerso H, Krarup T, Holst JJ. 2003. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J. Clin. Endocrinol. Metab. 88:220-244
73. Hansen L, Deacon CF, Orskov C, Holst JJ. 1999. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140:5356-633
74. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. 1996. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am. J. Physiol. Endocrinol. Metab. 271:E458-644
75. Ban K, Kim KH, Cho CK, Sauve M, Diamandis EP, et al. 2010. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 151:1520-311
76. Meier JJ, Gethmann A, Nauck MA, Gotze O, Schmitz F, et al. 2006. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. Am. J. Physiol. Endocrinol. Metab. 290:E1118-233
77. Deacon CF. 2005. What do we know about the secretion and degradation of incretin hormones? Regul. Pept. 128:117-244
78. Wei Y, Mojsov S. 1995. Tissue-specific expression of the human receptor for glucagon-like peptide-I: Brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 358:219-244
79. Bullock BP, Heller RS, Habener JF. 1996. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137:2968-788
80. Panjwani N, Mulvihill EE, Longuet C, Yusta B, Campbell JE, et al. 2013. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE mice. Endocrinology 154:127-399
81. Baggio LL, Huang Q, Brown TJ, Drucker DJ. 2004. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127:546-588
82. Scrocchi LA, Brown TJ, Maclusky N, Brubaker PL, Auerbach AB, et al. 1996. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat. Med. 2:1254-588
83. Lamont BJ, Li Y, Kwan E, Brown TJ, Gaisano H, Drucker DJ. 2012. Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. J. Clin. Investig. 122:388-4022
84. Xu G, Kaneto H, Laybutt DR, Duvivier-Kali VF, Trivedi N, et al. 2007. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 56:1551-588
85. Maida A, Lamont BJ, Cao X, Drucker DJ. 2011. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-in mice. Diabetologia 54:339-499
86. Kang ZF, Deng Y, Zhou Y, Fan RR, Chan JC, et al. 2013. Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the βcell in mouse models of diabetes. Diabetologia 56:423-333
87. Shu L, Matveyenko AV, Kerr-Conte J, Cho JH, McIntosh CH, Maedler K. 2009. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP-and GLP-1 receptors and impaired β-cell function. Hum. Mol. Genet. 18:2388-999
88. Buteau J, Foisy S, JolyE,PrentkiM.2003. Glucagon-like peptide 1 induces pancreatic β-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 52:124-322
89. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, et al. 2003. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144:5149-588
90. Yusta B, Baggio LL, Estall JL, Koehler JA, Holland DP, et al. 2006. GLP-1 receptor activation improves βcell function and survival following induction of endoplasmic reticulum stress. Cell Metab. 4:391-4066
91. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. 2013. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 62:2595-6044
92. Hare KJ, Vilsboll T, Asmar M, Deacon CF, Knop FK, Holst JJ. 2010. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes 59:1765-700
93. Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, et al. 2002. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J. Clin. Endocrinol. Metab. 87:1239-466
94. Tornehave D, Kristensen P, Romer J, Knudsen LB, Heller RS. 2008. Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J. Histochem. Cytochem. 56:841-511
95. Heller RS, Kieffer TJ, Habener JF. 1997. Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing cells of the rat endocrine pancreas. Diabetes 46:785-911
96. Gromada J, Franklin I, Wollheim CB. 2007. Cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr. Rev. 28:84-1166
97. Kawamori D, Welters HJ, Kulkarni RN. 2010. Molecular pathways underlying the pathogenesis of pancreatic cell dysfunction. Adv. Exp. Med. Biol. 654:421-455
98. Kielgast U, Asmar M, Madsbad S, Holst JJ. 2010. Effect of glucagon-like peptide-1 on and β-cell function in C-peptide-negative type 1 diabetic patients. J. Clin. Endocrinol. Metab. 95:2492-966
99. D'Alessio DA, Fujimoto WY, Ensinck JW. 1989. Effects of glucagonlike peptide I-(7-36) on release of insulin, glucagon, and somatostatin by rat pancreatic islet cell monolayer cultures. Diabetes 38:1534-388
100. de Heer J, Rasmussen C, Coy DH, Holst JJ. 2008. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 51:2263-700
101. Barrera JG, Sandoval DA, D'Alessio DA, Seeley RJ. 2011. GLP-1 and energy balance: an integrated model of short-term and long-term control. Nat. Rev. Endocrinol. 7:507-166
102. Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, et al. 2005. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res. 1044:127-311
103. Holst JJ. 2013. Incretin hormones and the satiation signal. Int. J. Obes. 37:1161-688
104. Lockie SH, Heppner KM, Chaudhary N, Chabenne JR, Morgan DA, et al. 2012. Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes 61:2753-622
105. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, et al. 1997. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am. J. Physiol. Endocrinol. Metab. 273:E981-888
106. Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, et al. 2003. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 88:2719-255
107. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML,UlusoyNB. 1997. Glucagonlike peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am. J. Physiol. Gastrointest. Liver Physiol. 273:G920-277
108. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. 2011. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 60:1561-655
109. Baggio LL, Kim JG, Drucker DJ. 2004. Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuateGLP-1R-dependent glucose homeostasis in vivo. Diabetes 53(Suppl. 3):205-144
110. Schjoldager BT, Mortensen PE, Christiansen J, Orskov C, Holst JJ. 1989. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig. Dis. Sci. 34:703-88
111. Wettergren A, Wojdemann M, Meisner S, Stadil F, Holst JJ. 1997. The inhibitory effect of glucagonlike peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 40:597-6011
112. Qin X, Shen H, Liu M, Yang Q, Zheng S, et al. 2005. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 288:G943-499
113. Meier JJ, Gethmann A, Gotze O, Gallwitz B, Holst JJ, et al. 2006. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 49:452-588
114. Hsieh J, Longuet C, Baker CL,Qin B, Federico LM, et al. 2010. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 53:552-611
115. McIntosh CH,Widenmaier S, Kim SJ. 2010. Pleiotropic actions of the incretin hormones. Vitam. Horm. 84:21-799
116. Luque MA, Gonzalez N, Marquez L, Acitores A, Redondo A, et al. 2002. Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes. J. Endocrinol. 173:465-733
117. Marquez L, Gonzalez N, Puente J, Valverde L, Villanueva-Penacarrillo ML. 2001. GLP-1 effect upon the GPI/IPG system in adipocytes and hepatocytes from diabetic rats. Diabetes Nutr. Metab. 14:239-444
118. Marquez L, Trapote MA, Luque MA, Valverde I, Villanueva-Penacarrillo ML. 1998. Inositolphosphoglycans possiblymediate the effects of glucagon-like peptide-1(7-36)amide on rat liver and adipose tissue. Cell Biochem. Funct. 16:51-566
119. Sancho V, Trigo MV, Gonzalez N, Valverde I, Malaisse WJ, Villanueva-Penacarrillo ML. 2005. Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats. J. Mol. Endocrinol. 35:27-388
120. Idris I, Patiag D, Gray S, Donnelly R. 2002. Exendin-4 increases insulin sensitivity via a PI-3-kinasedependent mechanism: contrasting effects of GLP-1. Biochem. Pharmacol. 63:993-966
121. Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, et al. 2011. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 60:1917-255
122. Sancho V, Trigo MV, Martn-Duce A, Gonzalez N, Acitores A, et al. 2006. Effect of GLP-1 on D-glucose transport, lipolysis and lipogenesis in adipocytes of obese subjects. Int. J. Mol. Med. 17:1133-377
123. Bertin E, Arner P, Bolinder J, Hagstrom-Toft E. 2001. Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo. J. Clin. Endocrinol. Metab. 86:1229-344
124. Lee YS, Park MS, Choung JS, Kim SS, Oh HH, et al. 2012. Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetologia 55:2456-688
125. Nogueiras R, Perez-Tilve D, Veyrat-Durebex C, Morgan DA, Varela L, et al. 2009. Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J. Neurosci. 29:5916-255
126. Valverde I, Morales M, Clemente F, Lopez-Delgado MI, Delgado E, et al. 1994. Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Lett. 349:313-166
127. Seghieri M, Rebelos E, Gastaldelli A, Astiarraga BD, Casolaro A, et al. 2013. Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia 56:156-611
128. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. 2006. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 43:173-811
129. Lee J, Hong SW, Chae SW, Kim DH, Choi JH, et al. 2012. Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice. PLoS ONE 7:e313944
130. Villanueva-Penacarrillo ML, Alcantara AI, Clemente F, Delgado E, Valverde I. 1994. Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia 37:1163-666
131. Yang H, Egan JM, Wang Y, Moyes CD, Roth J, et al. 1998. GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor. Am. J. Physiol. Cell Physiol. 275:C675-833
132. Johnson KM, Edgerton DS, Rodewald T, Scott M, Farmer B, et al. 2007. Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels. Am. J. Physiol. Endocrinol. Metab. 293:E1085-911
133. Chai W, Dong Z, Wang N, Wang W, Tao L, et al. 2012. Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes 61:888-966
134. Anagnostis P, Athyros VG, Adamidou F, Panagiotou A, Kita M, et al. 2011. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes. Metab. 13:302-122
135. Ussher JR, Drucker DJ. 2012. Cardiovascular biology of the incretin system. Endocr. Rev. 33:187-2155
136. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, et al. (SAVOR-TIMI 53 Steer. Comm. Investig.). 2013. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369:1317-266
137. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, et al. (EXAMINE Investig.). 2013. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 369:1327-355
138. Nathanson D, Erdogdu O, Pernow J, Zhang Q, Nystrom T. 2009. Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo. Regul. Pept. 157:8-133
139. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. 2006. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J. Cardiac Fail. 12:694-999
140. Yerram P, Whaley-Connell A. 2012. Novel role for the incretins in blood pressure regulation. Curr. Opin. Nephrol. Hypertens. 21:463-688
141. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, et al. 2013. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat. Med. 19:567-755
142. Rieg T, Gerasimova M, Murray F, Masuda T, Tang T, et al. 2012. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am. J. Physiol. Ren. Physiol. 303:F963-711
143. Holst JJ, Burcelin R, Nathanson E. 2011. Neuroprotective properties ofGLP-1: theoretical and practical applications. Curr. Med. Res. Opin. 27:547-588
144. Yamada C, Yamada Y, Tsukiyama K, Yamada K, Udagawa N, et al. 2008. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology 149:574-799
145. Nuche-Berenguer B, Portal-Nunez S, Moreno P, Gonzalez N, Acitores A, et al. 2010. Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor. J. Cell. Physiol. 225:585-922
146. Rubino F, R'bibo SL, del Genio F, Mazumdar M, McGraw TE. 2010. Metabolic surgery: the role of the gastrointestinal tract in diabetes mellitus. Nat. Rev. Endocrinol. 6:102-99
147. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, et al. 2012. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N. Engl. J. Med. 366:1577-855
148. Stefater MA, Wilson-Perez HE, Chambers AP, Sandoval DA, Seeley RJ. 2012. All bariatric surgeries are not created equal: insights from mechanistic comparisons. Endocr. Rev. 33:595-6222
149. Jørgensen NB, Dirksen C, Bojsen-Møller KN, Jacobsen SH, Worm D, et al. 2013. The exaggerated glucagon-like peptide-1 response is important for the improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes 62:3044-522
150. Jimenez A, Casamitjana R, Viaplana-Masclans J, Lacy A, Vidal J. 2013. GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes after gastric bypass surgery. Diabetes Care 36:2062-699
151. Bush MA, Matthews JE, De Boever EH, Dobbins RL, Hodge RJ, et al. 2009. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes. Metab. 11:498-5055
152. Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R. 2009. Treatmentwith the human onceweekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. Diabetes Care 32:1237-433
153. Leger R, Thibaudeau K, Robitaille M, Quraishi O, vanWyk P, et al. 2004. Identification of CJC-1131-albumin bioconjugate as a stable and bioactiveGLP-1(7-36) analog. Bioorg.Med. Chem. Lett. 14:4395-988
154. Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, et al. 2000. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. 43:1664-699
155. Riedel MJ, Kieffer TJ. 2010. Treatment of diabetes with glucagon-like peptide-1 gene therapy. Expert Opin. Biol. Ther. 10:1681-922
156. Deacon CF. 2011. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes. Metab. 13:7-188
157. Singh S, Chang HY, Richards TM,Weiner JP, Clark JM, Segal JB. 2013. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern. Med. 173:534-399
158. Butler PC, Elashoff M, Elashoff R, Gale EA 2013. A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe? Diabetes Care 36:2118-255
159. Nauck MA. 2013. A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks. Diabetes Care 36:2126-322
160. Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. 2011. The safety of incretin-based therapies -review of the scientific evidence. J. Clin. Endocrinol. Metab. 96:2027-311
161. Chen D, Liao J, Li N, Zhou C, Liu Q, et al. 2007. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proc. Natl. Acad. Sci. USA 104:943-488